Covexin 10

Main information

Documents

Localization

  • Available in:
  • Covexin 10
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Cattle, Sheep

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0201/001
  • Authorization date:
  • 11-03-2011
  • EU code:
  • UK/V/0201/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:June2013

AN:00069/2013

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Covexin10SuspensionforInjectionforSheepandCattle

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

ActiveIngredients Potencyvalue/mL

C.perfringenstypeAtoxoid

0.5U #

C.perfringenstypeB&C( β)

toxoid

18.2IU*

C.perfringenstypeD( ε)toxoid

5.3IU*

C.chauvoeiwholeculture meetsPhEur.**

C.novyitoxoid

3.8IU*

C.septicumtoxoid

4.6IU*

C.tetanitoxoid

4.9IU*

C.sordelliitoxoid

4.4U 1

C.haemolyticumToxoid

17.4U #

Adjuvant

Alum 3.03 –4.09mg/mLAluminium

Preservative

Thiomersal 0.05 –0.18mg/mL

Excipientto1ml

Formaldehyde

0.5mg/mL

*ELISAAccordingtoPh.Eur

**ChallengetestaccordingtoPh.Eur.

1

InHouseELISA

Invitrotoxinneutralisationtestbasedonhaemolysisofsheeperythrocytes.

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Suspensionforinjection

Lightbrownaqueoussuspensionthatsettlesonstorage

4.CLINICALPARTICULARS

4.1Targetspecies

Sheepandcattle

Revised:June2013

AN:00069/2013

Page2of6

4.2Indicationsforuse,specifyingthetargetspecies

Fortheactiveimmunisationofsheepandcattleagainstdiseasesassociatedwith

infectionscausedbyClostridiumperfringenstypeA,C.perfringenstypeB,C.

perfringenstypeC,C.perfringenstypeD,Clostridiumchauvoei,Clostridiumnovyi

typeB,Clostridiumsepticum,ClostridiumsordelliiandClostridiumhaemolyticumand

againsttetanuscausedbyClostridiumtetani.

Forthepassiveimmunisationoflambsandcalvesagainstinfectionscausedbythe

abovementionedclostridialspecies(exceptC.haemolyticuminsheep).

Theonsetofimmunityistwoweeksaftertheprimarycourse.

Durationofactiveimmunity

Ananamnestichumoralimmuneresponse(immunologicalmemory)toall

componentswasdemonstrated12monthsfollowingtheprimarycourseof

vaccination.

Asdemonstratedbyserology/persistentantibodytitreonly:

Sheep:12monthsagainstC.perfringenstypeA,B,CandD,C.novyitypeB,C.

sordellii,C.tetani

<6monthsagainstC.septicum,C.haemolyticum,C.chauvoei

Cattle:12monthsagainstC.tetaniandC.perfringenstypeD

<12monthsagainstC.perfringenstypeA,BandC

<6monthsagainstC.novyitypeB,C.septicum,C.sordellii,C.haemolyticum,C.

chauvoei

Durationofpassiveimmunityasdemonstratedbyserology/persistentantibodytitre

onlyis

Forlambs:

Atleast2weeksforC.septicumandC.chauvoei,atleast8weeksforC.perfringens

typeBandC.perfringenstypeCandatleasttwelveweeksforC.perfringenstypeA,

C.perfringenstypeD,C.novyitypeB,C.tetaniandC.sordellii.Nopassive

immunitywasobservedforC.haemolyticum.

Forcalves:

Atleast2weeksforC.sordellii,andC.haemolyticum,atleast8weeksforC.

septicumandC.chauvoeiandatleasttwelveweeksforC.perfringenstypeA,C.

perfringenstypeB,C.perfringenstypeC,C.perfringenstypeD,C.novyitypeB,and

C.tetani.

4.3Contraindications

None

4.4Specialwarnings

Theeffectivenessofthevaccineinprovidingpassiveimmunitytoyounglambsand

calvesdependsontheseanimalsingestingadequateamountsofcolostrumonthe

firstdayoflife.

Clinicaltrialshavedemonstratedthatthepresenceofmaternalantibodies,

particularlyagainstC.tetani,C.novyitypeB,C.perfringenstypeA(calvesonly),C.

chauvoei(lambsonly)andC.perfringenstypeDmayreducetheantibodyresponse

tovaccinationinyounglambsandcalves.Therefore,toensureanoptimal

Revised:June2013

AN:00069/2013

Page3of6

responseinyounganimalswithhighlevelsofMDA,theprimaryvaccinationshould

bedelayeduntilthelevelswane(whichisafterabout8-12weeksofage,seesection

4.2).

4.5Specialprecautionsforuse

i Specialprecautionsforuseinanimals

Intheeventofananaphylacticreactionappropriatetreatmentsuch

asadrenalineshouldbeadministeredwithoutdelay.

Donotvaccinatesickorimmunodeficientanimals.

iiSpecialprecautionstobetakenbythepersonadministering

theveterinarymedicinalproducttoanimals

Incaseofaccidentalself-injection,seekmedicaladviceimmediately

andshowthepackageleafletorthelabeltothephysician.

4.6Adversereactions(frequencyandseriousness)

75-100%ofanimalsvaccinatedwithCovexin10mayexperiencereactionsto

vaccination.Thesereactionsareusuallylocalisedswellingorindurationatthe

injectionsitebutmayalsoincludemildhyperthermia,abscessorotherreactioninthe

underlyingtissuesattheinjectionsite.

Swellingattheinjectionsiteoccursinthemajorityofanimals.Thismayreachuptoa

meanvalueof6cminsheepand15cmdiameterincattle;occasionallyreactionsof

upto25cmdiametermaybeseenincattle.Mostlocalreactionsresolvewithin3-6

weeksinsheepandinlessthan10weeksincattle,butmaypersistlongerina

minorityofanimals.Anabscessmaydevelopinsomeanimals.Vaccinationmaygive

risetoreactionsintheunderlyingtissuesattheinjectionsite.

Skindiscolourationattheinjectionsite(whichreturnstonormalasthelocaleaction

resolved)mayoccur.Localisedpainattheinjectionsitefor1-2dayspostfirst

vaccinationmayoccur.

Thelocalreactionsdonotaffectthegeneralhealth,demeanour,feedingorweight

gainoftheanimals.

4.7Useduringpregnancy,lactationorlay

Pregnancy:

Nosideeffectsotherthanthosedescribedunder4.6wereseenwhenthevaccine

wasusedinsheepandcattlebetween8and2weekspriortoparturition.Inthe

absenceofspecificdata,norecommendationcanbemadeforuseofthevaccine

duringthefirstorsecondthirdofpregnancy.

Avoidstressinpregnantewesandcows.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noinformationisavailableonthesafetyandefficacyofthisvaccinewhenusedwith

anyotherveterinarymedicinalproduct.Adecisiontousethisvaccinebeforeorafter

Revised:June2013

AN:00069/2013

Page4of6

anyotherveterinarymedicinalproductthereforeneedstobemadeonacaseby

casebasis.

4.9Amountstobeadministeredandadministrationroute

Sheep –from2weeksofage

Dose-1ml

Cattle –from2weeksofage

Dose –2ml

Administration:Bysubcutaneousinjectionatasuitablesite.Therecommendedsite

isthelooseskinonthesideoftheneck.

Thebottleshouldbewellshakenbeforeanyvaccineiswithdrawn.

Syringesandneedlesshouldbesterilebeforeuseandtheinjectionshouldbemade

throughanareaofclean,dryskintakingprecautionsagainstcontamination.

Primaryvaccination:Twodosesshouldbeadministered,4-6weeksapart(see

section4.2and4.4).

Boostervaccination:Asingledoseshouldbeadministeredat6to12monthintervals

(seealsopoint4.2).

Useinpregnancy

Toprovidepassiveprotectionoftheoffspring,viathecolostrum,asinglebooster

doseshouldbeadministeredbetween8and2weeksbeforeparturition,providedthat

animalshavereceivedafullprimaryvaccinationcoursebeforepregnancy.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incalvesandlambs,localreactionsmayincreaseslightlyiftwicetherecommended

doseisadministered(refertosection4.6)

4.11Withdrawalperiod(s)

Zerodays.

5. IMMUNOLOGICALPROPERTIES

ImmunologicalforBovidae:QI02AB01

ImmunologicalforOvidae:QI04AB01

TostimulateactiveimmunityinsheepandcattleagainstC.chauvoeiandthetoxins

ofClostridiumperfringenstypeA,C.perfringenstypeB,C.perfringenstypeC,C.

perfringenstypeD,C.novyi,C.septicum,C.tetani,C.sordellii,andC.haemolyticum

containedinthevaccine.

Toprovidepassiveimmunityviathecolostrumagainsttheaboveclostridialinfections

inyounglambsandcalves

Revised:June2013

AN:00069/2013

Page5of6

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Alum

Thiomersal

Formaldehyde

SodiumChloride(0.85%solution)

6.2Incompatibilities

Donotmixwithanyothervaccine/immunologicalproduct.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:30months

Shelflifeafterfirstopeningtheimmediatepackaging:8hours

6.4.Specialprecautionsforstorage

Storeandtransportbetween+2°Cand+8°C.Protectfromlight.Donotfreeze.

6.5Natureandcompositionofimmediatepackaging

Cardboardboxwith1of50mlor100mlflexiblehighdensitypolyethylenebottleand

closedwithapharmaceuticalgraderubberbungheldinplacewithanaluminium

seal.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

PfizerLtd

RamsgateRoad

Sandwich

Kent

CT139NJ

Revised:June2013

AN:00069/2013

Page6of6

8.MARKETINGAUTHORISATIONNUMBER

Vm 00057/4282

9.DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Date:10March2003

10.DATEOFREVISIONOFTHETEXT

Date:June2013

APPROVED 4/07/13

26-10-2018

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Published on: Thu, 25 Oct 2018 00:00:00 +0200 A multi-country outbreak of 12 listeriosis cases caused by Listeria monocytogenes sequence type (ST) 8 has been identified through whole genome sequencing (WGS) analysis in three EU/EEA countries: Denmark (6 cases), Germany (5) and France (1). Four of these cases have died due to or with the disease. It is likely that the extent of this outbreak has been underestimated since the outbreak was identified through sequencing and only a subset of the EU/EEA count...

Europe - EFSA - European Food Safety Authority Publications

There are no news related to this product.